European Parliament Continues to Recognize Primary Woody Biomass as a Renewable Energy Source
14.9.2022 18:49:00 EEST | Business Wire | Press release
Today, the European Parliament once again voted to recognize primary woody biomass as a renewable energy source. This is consistent with its prior classification under both the first Renewable Energy Directive (RED) and RED II. Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, welcomes the designation as it marks a critical step in the right direction toward more low-carbon, drop-in alternatives to fossil fuels for power and heat generation, as part of an all-in renewables strategy to reduce carbon emissions and limit global dependence on fossil fuels.
Primary woody biomass is an essential renewable energy source for meeting the ambition sought by the EU Parliament to increase renewable energy to 45 percent by 2030, and for achieving the EU’s goal of carbon neutrality by 2050. In the words of Markus Pieper, the Member of Parliament leading on RED III, at the press conference held following the results of the plenary, “We do need wood-based biomass as a source of energy if we genuinely are to undertake this energy transition.”
The Parliament’s vote this week brings its position considerably closer to those of the Council and EU Commission by recognizing primary woody biomass as renewable, ensuring its continued zero-carbon rating in the EU Emissions Trading Scheme, and allowing its use to increase in volume.
“One thing is clear: wood-based biomass is a building block of the energy transition and, despite the vote of left-green Members of the European Parliament, can still be counted as renewable energy. The new directive will set the necessary framework to achieve the greatest possible CO2 reduction effect and not to ensure that our forests are burned in the future. I am counting on the member states to follow our proposals as the procedure progresses (“trilogue”),” continued Mr. Pieper in his statement.
The Council and EU Commission have continued their steadfast support for primary woody biomass and for its increased utilization to deliver climate change benefits and security of energy supply. Today’s vote serves as an initial negotiating position in the European Union’s process. After this vote, the EU Parliament, the Council of the EU, and the EU Commission will begin trilogue discussions, which are negotiations among the three parties, that are estimated to reach a final compromise on RED III in the first half of 2023.
“Heading into trilogues, the EU Parliament brought its position one step closer towards the mainstream views of the Council and the Commission, and away from the earlier minority position taken by the ENVI committee.
“While the process is foreign to those of us in the U.S., as an Austrian native, I can appreciate the complex nature of the EU legislative process, and that a compromise needs to be reached in trilogue negotiations to address the energy transition, security, and affordability crisis facing the EU. Today, biomass accounts for almost 60 percent of renewable energy in Europe.
“All serious pathways for achieving climate neutrality show that the use of bioenergy must and can be increased sustainably. The EU Commission’s own impact assessment for RED III outlines a need to increase bioenergy use from 2030 to 2050 by an average of 69 percent to provide vital grid balancing services, high temperature heat for industry, advanced biofuels, and negative emissions,” said Thomas Meth, President of Enviva.
“A failure to increase woody biomass use in the EU would mean failure in meeting climate goals, increased cost to EU consumers, and further disruption to security of energy supply on the brink of winter, when bioenergy makes up 25 percent of European heating supply and when incremental investments in more woody biomass infrastructure are desperately needed. At Enviva, we are encouraged by the progress made and are confident that a pragmatic and reasonable outcome will be reached,” concluded Meth.
About Enviva
Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.
To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005763/en/
Contact information
MEDIA:
media@envivabiomass.com
+1 240-856-0324
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
